Hydrochloric Acid

Hydrochloric Acid

SCHEMBL1603386

CC(C)(C)P(c1ccccc1)C(C)(C)C.CC(C)(C)P(c1ccccc1)C(C)(C)C.[Cl-].[Cl-].[Pd+2]

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A2 known ✓ P23975 1/20 0.31
ACHE known ✓ P22303 1/20 0.30
CYP3A4 P08684 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALDH1A1 P00352 2/20 0.36
ALOX15 P16050 1/20 0.36
ESR1 P03372 6/20 0.34
ESR2 Q92731 6/20 0.34
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
MAPK1 P28482 1/20 0.33
TAAR1 Q96RJ0 2/20 0.31
TSHR P16473 2/20 0.30
LMNA P02545 1/20 0.30
ALOX12 P18054 1/20 0.30
KCNN4 O15554 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27810339 1.00 CYP3A4 (0.41) CYP3A4TDP1ALDH1A1ALOX15ESR1
SCHEMBL289857 0.95 CYP3A4 (0.45) CYP3A4TDP1ALDH1A1ALOX15ESR1
Hydrochloric Acid SCHEMBL31568007 0.92 CYP3A4 (0.43) CYP3A4TDP1ALDH1A1ALOX15ESR1
SCHEMBL18796532 0.92 CYP3A4 (0.43) CYP3A4TDP1ALDH1A1ALOX15ESR1
SCHEMBL19093066 0.92 CYP3A4 (0.43) CYP3A4TDP1ALDH1A1ALOX15ESR1
Bromide SCHEMBL28700347 0.92 CYP3A4 (0.43) CYP3A4TDP1ALDH1A1ALOX15ESR1
Hydrochloric Acid SCHEMBL31467528 0.92 CYP3A4 (0.43) CYP3A4TDP1ALDH1A1ALOX15ESR1
SCHEMBL3645144 0.92 CYP3A4 (0.43) CYP3A4TDP1ALDH1A1ALOX15ESR1
SCHEMBL14696690 0.92 CYP3A4 (0.43) CYP3A4TDP1ALDH1A1ALOX15ESR1
SCHEMBL28001639 0.87 CYP3A4 (0.39) CYP3A4TDP1ALDH1A1ALOX15ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021114639-A1 NEW-TYPE OXAZOLIDINONE COMPOUNDS AND PREPARATION METHOD THEREFOR 华创合成制药股份有限公司 2021-06-17 WO disclosed
US-10392476-B2 Polymers comprising amino dihydrophenanthrene repeating units and organic electronic devices using the same CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2019-08-27 US disclosed
EP-2949655-B1 REACTION CATALYST FOR CROSS COUPLING AND METHOD FOR MANUFACTURING AROMATIC COMPOUND HOKKO CHEM IND CO (JP) 2019-05-15 EP disclosed
US-20180171076-A1 POLYMER AND DEVICE CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2018-06-21 US disclosed
US-9707551-B2 Reaction catalyst for cross-coupling and method for manufacturing aromatic compound HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) 2017-07-18 US disclosed
US-20150360214-A1 REACTION CATALYST FOR CROSS-COUPLING AND METHOD FOR MANUFACTURING AROMATIC COMPOUND HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) 2015-12-17 US disclosed
EP-2949655-A1 REACTION CATALYST FOR CROSS COUPLING AND METHOD FOR MANUFACTURING AROMATIC COMPOUND Hokko Chemical Industry Co., Ltd. (JP) 2015-12-02 EP disclosed
EP-2364976-B1 S1P receptor modulating compounds and use thereof EPIX PHARM INC (US) 2014-10-08 EP disclosed
EP-2364976-A1 S1P receptor modulating compounds and use thereof EPIX Pharmaceuticals, Inc. (US) 2011-09-14 EP disclosed
US-20110212940-A1 S1P Receptor Modulating Compounds and Use Thereof EPIX PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20080027036-A1 S1P receptor modulating compounds and use thereof EPIX DELAWARE, INC. (US) 2008-01-31 US disclosed
US-7312350-B2 Process for preparing arylalkynes LANXESS DEUTSCHLAND GMBH (DE) 2007-12-25 US disclosed
WO-2007109334-A2 SIP RECEPTOR MODULATING COMPOUNDS AND USE THEREOF EPIX DELAWARE, INC. (US) 2007-09-27 WO disclosed
US-7238722-B2 process which start from easily obtainable reactants to form pyrazolylalkines, used as chemical intermediates for acaricides and insecticdes LANXESS DEUTSCHLAND GMBH (DE) 2007-07-03 US disclosed
US-7102046-B2 By reaction of haloaromatics or arylsulfonates with olefins in presence of palladium catalyst, bulky nitrogen base and salt BAYER AKTIENGESELLSCHAFT (DE) 2006-09-05 US disclosed
US-6916839-B2 Pyrazolylarylalkines BAYER CHEMICALS AKTIENGESELLSCHAFT (DE) 2005-07-12 US disclosed
US-20040229929-A1 Pyrazolylalkines LANXESS DEUTSCHLAND GMBH (DE) 2004-11-18 US disclosed
US-20040192952-A1 Process for preparing arylalkynes LANXESS DEUTSCHLAND GMBH (DE) 2004-09-30 US disclosed
US-20040142820-A1 Pyrazolylarylalkines VENTURE LENDING & LEASING IX, INC. 2004-07-22 US disclosed
US-20030105353-A1 Process for the arylation of olefins LANXESS DEUTSCHLAND GMBH (DE) 2003-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027036-A1 S1P receptor modulating compounds and use thereof S1PR1, S1PR5, S1PR2 SLC6A2 3530/4885ACHE 2843/4885CYP3A4 2766/4885
US-20040229929-A1 Pyrazolylalkines CX3CR1, PROKR2, BDKRB2 SLC6A2 4462/4885ACHE 999/4885CYP3A4 277/4885
US-20030105353-A1 Process for the arylation of olefins NEK6, JUN, AOC2 SLC6A2 162/4885ACHE 4596/4885CYP3A4 314/4885
US-20110212940-A1 S1P Receptor Modulating Compounds and Use Thereof S1PR1, S1PR5, S1PR2 SLC6A2 3530/4885ACHE 2843/4885CYP3A4 2766/4885
US-20150360214-A1 REACTION CATALYST FOR CROSS-COUPLING AND METHOD FOR MANUFACTURING AROMATIC COMPOUND ALK, HRH4, HRH3 SLC6A2 3809/4885ACHE 1033/4885CYP3A4 237/4885
US-20040192952-A1 Process for preparing arylalkynes ARSA, STS, HDHD5 SLC6A2 1093/4885ACHE 4109/4885CYP3A4 98/4885
US-20040142820-A1 Pyrazolylarylalkines CBR3, PPOX, ALK SLC6A2 4324/4885ACHE 905/4885CYP3A4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.